ASND (Ascendis Pharma AS) Cyclically Adjusted Revenue per Share: $3.22 (As of Mar. 2026)


ASND Ascendis Pharma AS ASND
37 GF Score
Price $274.50
! 5 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Cyclically Adjusted Revenue per Share?

Ascendis Pharma AS ASND +2.52% 37 Cyclically Adjusted Revenue per Share is $3.22 as of Mar. 2026. GuruFocus rates ASND with a GF Score™ of 37/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ascendis Pharma AS's adjusted revenue per share for the three months ended in Mar. 2026 was $4.418. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $3.22 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ascendis Pharma AS's average Cyclically Adjusted Revenue Growth Rate was 98.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-05), Ascendis Pharma AS's current stock price is $274.50. Ascendis Pharma AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $3.22. Ascendis Pharma AS's Cyclically Adjusted PS Ratio of today is 85.25.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ascendis Pharma AS was 85.25. The lowest was 65.36. And the median was 71.69.


Ascendis Pharma AS  (NAS:ASND) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ascendis Pharma AS's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=274.50/3.22
=85.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ascendis Pharma AS was 85.25. The lowest was 65.36. And the median was 71.69.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ascendis Pharma AS Cyclically Adjusted Revenue per Share Related Terms


Ascendis Pharma AS Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Cyclically Adjusted Revenue per Share Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.83 1.44 2.77

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.62 1.90 2.32 2.77 3.22

ASND vs JAZZ, BBIO, EXEL: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Cyclically Adjusted PS Ratio falls into.


ASND
37GF Score
Ascendis Pharma AS ASND
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ascendis Pharma AS's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.418/121.6800*121.6800
=4.418

Current CPI (Mar. 2026) = 121.6800.

Ascendis Pharma AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.051 100.600 0.062
201609 0.052 100.200 0.063
201612 0.036 100.300 0.044
201703 0.012 101.200 0.014
201706 0.015 101.200 0.018
201709 0.016 101.800 0.019
201712 0.009 101.300 0.011
201803 0.001 101.700 0.001
201806 0.001 102.300 0.001
201809 0.001 102.400 0.001
201812 0.284 102.100 0.338
201903 0.141 102.900 0.167
201906 0.077 102.900 0.091
201909 0.052 102.900 0.061
201912 0.058 102.900 0.069
202003 0.051 103.300 0.060
202006 0.034 103.200 0.040
202009 0.062 103.500 0.073
202012 0.012 103.400 0.014
202103 0.017 104.300 0.020
202106 0.023 105.000 0.027
202109 0.024 105.800 0.028
202112 0.097 106.600 0.111
202203 0.133 109.900 0.147
202206 0.117 113.600 0.125
202209 0.271 116.400 0.283
202212 0.434 115.900 0.456
202303 0.641 117.300 0.665
202306 0.913 116.400 0.954
202309 0.911 117.400 0.944
202312 2.384 116.700 2.486
202403 1.832 118.400 1.883
202406 0.637 118.500 0.654
202409 1.116 118.900 1.142
202412 3.045 118.900 3.116
202503 1.818 120.200 1.840
202506 2.852 120.700 2.875
202509 4.127 121.600 4.130
202512 4.736 121.200 4.755
202603 4.418 121.680 4.418

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $3.22 mean?
Ascendis Pharma AS (ASND) has a Cyclically Adjusted Revenue per Share of $3.22 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ascendis Pharma AS and its competitors.
Is Ascendis Pharma AS's Cyclically Adjusted Revenue per Share too high?
Ascendis Pharma AS's current Cyclically Adjusted Revenue per Share is $3.22. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Cyclically Adjusted Revenue per Share compare to JAZZ and BBIO?
Ascendis Pharma AS's Cyclically Adjusted Revenue per Share of $3.22 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current Cyclically Adjusted Revenue per Share is $3.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current Cyclically Adjusted Revenue per Share of $3.22. The current Cyclically Adjusted Revenue per Share is $3.22. Ascendis Pharma AS's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current Cyclically Adjusted Revenue per Share is $3.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges A1SN34:Brazil
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for ASND

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$274.50
Price